Yuichi Iwaki, M.D., Ph.D., MediciNova CEO commented, “The successful resolution of the Sanofi-Novartis litigation and the resulting monetary damages due to MediciNova both validates the value of our ...
LA JOLLA, Calif., Oct. 23, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock ...
It is doubtless a positive to see that the MediciNova, Inc. (NASDAQ:MNOV) share price has gained some 45% in the last three months. But will that heal all the wounds inflicted over 5 years of ...
MediciNova (MNOV) was notified by Sanofi (SNY) that the Sanofi/Novartis (NVS) litigation was settled. Accordingly, MediciNova is entitled to ...
MediciNova, Inc. (NASDAQ:MNOV – Get Free Report) shares crossed above its 200-day moving average during trading on Wednesday .The stock has a 200-day moving average of $1.50 and traded as high ...
Shares of MariaDB plc (NYSE: MRDB) rose sharply in today’s pre-market trading after Progress Software (NASDAQ: PRGS) announced that it is possibly considering an offer for the company. Avi ...
MediciNova, Inc. is a biopharmaceutical company, which engages in the acquisition and development of small molecule therapeutics for the treatment of diseases with unmet medical needs. The company ...
StockNews.com assumed coverage on shares of MediciNova (NASDAQ:MNOV – Free Report) in a report released on Wednesday. The firm issued a hold rating on the biopharmaceutical company’s stock. MediciNova ...
DelveInsight’s, “Interstitial Lung Diseases Pipeline Insight 2024” report provides comprehensive insights about 120+ ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback